- Insilico Medicineachievedan R&D collaborationwith Serviervalued at up toUS$888 million, focused on discovering and developing innovative oncology therapies, by combiningInsilico’sAI-driven drug discovery platforms with Servier’s global expertise in cancer drug development.
- Under the terms of the agreement,Insilico will be eligible to receive up to US$32 million in upfront and near-term R&D payments and will leverage its proprietary AI-powered technologies to identify and advance potential drug candidates that meet predefined scientific and development criteria.
- Servier willparticipatein sharing research and development costs, and, upon the successful identification of promising candidates, willleadsubsequentclinical validation, regulatory interactions, and worldwide commercialization of the resulting oncology drug candidates.
CAMBRIDGE, Mass., Jan. 4, 2026 /PRNewswire/ — Insilico Medicine(“Insilico”), a world-leading artificial intelligence (AI)-driven drug discovery company,today announced a multi-year research and development (R&D) collaborationwith Servier, an independent international pharmaceutical company governed by a foundation.This strategic alliance is focused onidentifyingand developing novel therapeutics for challenging targets in theoncology spaceby leveraging Insilico’s proprietary AI platform,Pharma.AI.
Under the agreement, Insilico will be eligible to receive up toUS$32million in upfront and near-term R&D payments and will lead the AI-driven discovery and development of potential drug candidates that meet predefined criteria, while Servier will share the R&D expenses andleadclinical validation and commercialization processes.
“This collaboration underscores Servier’s commitment to applying cutting-edge technologies to address unmet medical needs for the benefit of patients and reflectsourconfidence inInsilico’sinternally developed and validated AI platform”,saidChristopheThurieau,Executive Director Research at Servier.
“I am excited to see the collaboration—it is yet another strong acknowledgment of our AI capabilities and R&D expertise”,saidAlex Zhavoronkov, PhD, founder,CEOandCBOof Insilico Medicine. “As we deepen the integration of generative AI into every stage of the pharma value chain, I believe the future of pharmaceutical superintelligence is never so close, where AI agents could actually make decisions and design experiments, driving a virtuous cycle of faster, smarter, and safer drug development.”
Insilico has extensive experience in AI-drivenoncologydrug discovery and development. The company hasestablisheda robust oncology pipeline that targets multiple cancer indications,leveragingboth moderately novel and well-established mechanisms. Among its most promising assets, the potential best-in-class pan-TEAD inhibitor ISM6331 and the MAT2A inhibitor ISM3412 are both undergoing global, multicenter Phase I clinical trials. Additionally, four otheroncology programs have beenfully or partiallyout-licensedto partners, with Phase I clinical trials actively in progress.
Harnessingstate-of-the-artAI and automation technologies, Insilico has significantly improved the efficiency of preclinical drug development, setting abenchmarkfor AI-driven drug R&D.While traditional early-stage drug discovery typically requiresan average of4.5years, Insilico has nominated 20 preclinical candidatesfrom 2021 to 2024,with an average timeline—from project initiation to preclinical candidate (PCC) nomination—of just 12 to 18 months per program, with only 60 to 200 molecules synthesized and tested in each program.
About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend health longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.
By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritionalproductsand veterinary medicine. For more information, please visitwww.insilico.com
SOURCE Insilico Medicine